Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock Price Down 7.1%

Shares of Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) traded down 7.1% on Thursday . The company traded as low as $6.47 and last traded at $6.56. 327,591 shares changed hands during trading, an increase of 1% from the average session volume of 324,656 shares. The stock had previously closed at $7.06.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, April 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, April 1st. Maxim Group upped their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, March 19th. Finally, StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, March 19th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $25.72.

Actinium Pharmaceuticals Price Performance

The firm has a market cap of $192.86 million, a price-to-earnings ratio of -3.58 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last released its quarterly earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.21. The firm had revenue of $0.08 million for the quarter. As a group, equities analysts anticipate that Actinium Pharmaceuticals, Inc. will post -1.87 EPS for the current year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ATNM. Brandywine Global Investment Management LLC purchased a new stake in Actinium Pharmaceuticals in the 3rd quarter worth $1,033,000. Sanders Morris Harris LLC purchased a new stake in Actinium Pharmaceuticals in the 1st quarter worth $78,000. Finally, Creative Financial Designs Inc. ADV increased its stake in Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after buying an additional 3,175 shares in the last quarter. 27.50% of the stock is owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.